Why Clovis Oncology's Stock Is Trading Higher Today

Clovis Oncology CVLS shares are trading higher on Monday after the Journal Of Clinical Oncology published data from the Phase 2 TRITON2 study of Rubraca for the treatment of mCRPC in patients with BRCA1/2 gene mutations.

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations.
Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the U.S. for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.

Clovis Oncology shares were trading up 19.19% at $5.74 at the time of publication on Monday. The stock has a 52-week high of $17.37 and a 52-week low of $2.93.